Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?

Stellini, Roberto; Gianello, Renzo; Gomarasca, Walter

Stellini, Roberto; Gianello, Renzo; Gomarasca, Walter.

Afiliação

Stellini R; Infectious Diseases Service, Health Care Department, Poliambulanza Foundation Hospital, Via Bissolati, 57-25124, Brescia, Italy. roberto.stellini@poliambulanza.it.
Gianello R; Department of Clinical Laboratory, Poliambulanza Foundation Hospital, Brescia, Italy.
Gomarasca W; Health Care Department, Poliambulanza Foundation Hospital, Brescia, Italy.

Infection ; 50(6): 1573-1577, 2022 Dec.

Article em En | MEDLINE | ID: mdl-35391649

Assuntos

Vacinas contra COVID-19; COVID-19; Humanos; COVID-19/prevenção & controle; RNA Mensageiro; Vacina BNT162; Estudos Prospectivos; SARS-CoV-2; Vacinação; Imunoglobulina G; Anticorpos Antivirais

Palavras-chave

Anti spike antibodies; BNT162b2; Immunization; SARS-CoV-2; Vaccine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google